Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with a very poor prognosis. There are various subtypes of PDAC including Adenosquamous carcinoma, Colloid carcinoma (mucinous non-cystic carcinoma), Hepatoid carcinoma, Medullary carcinoma, Signet ring cell carcinoma, Undifferentiated carcinoma, Undifferentiated carcinoma with osteoclast-like giant cells and others. Currently, studies on prognostic modeling of pancreatic malignancies have focused on PDAC, however, due to the paucity of reports on colloid carcinoma and the small sample size of studies, there has never been a consensus on its prognostic risk factors. Against this background, we propose the following specific objectives for this study: 1) to clarify the risk factors affecting the prognosis of CC; 2) to construct a clinical prognostic model; and 3) to evaluate the prognosis of patients on survival. Methods: In this study, 510 patients from the SEER database were selected and divided into a training set and a validation set, and a prognostic model was developed based on the clinical variables in the training set to predict the probability values of cancer-specific survival of CC at 1, 3, and 5 years, whereas the validation set was used to validate the variables screened in the training cohort and to calibrate the predictive model. Results: In this study, the SEER database was used to explore the risk factors affecting the prognosis of CC: age, gender, RN examined, surgery, T stage, and metastasis. Conclusion: In this study, a clinical prognostic model was constructed, and the survival prognosis of patients was effectively evaluated using this model, filling the gap in the prognostic studies of this rare tumor. It provides a powerful basis for clinicians to assess the prognosis of patients.